Document is current
Any future updates will be listed below
-
Authors
Vaparanta, Katri https://orcid.org/0000-0002-3574-4427
Jokilammi, Anne https://orcid.org/0000-0002-1675-5737
Paatero, Ilkka https://orcid.org/0000-0001-5926-2396
Merilahti, Johannes A https://orcid.org/0000-0002-9113-5175
Heliste, Juho https://orcid.org/0000-0003-0182-2746
Hemanthakumar, Karthik Amudhala https://orcid.org/0000-0001-6151-1005
Kivelä, Riikka https://orcid.org/0000-0002-2686-8890
Alitalo, Kari https://orcid.org/0000-0002-7331-0902
Taimen, Pekka https://orcid.org/0000-0001-8849-4604
Elenius, Klaus https://orcid.org/0000-0001-5700-0827
-
Funding
Funding for this research was provided by:
Aarne Koskelon Säätiö
Academy of Finland
Cancer Society of Southwestern Finland
Emil Aaltosen Säätiö
K. Albin Johanssons Stiftelse
Maud Kuistilan Muistosäätiö
Orionin Tutkimussäätiö
Paavo Nurmen Säätiö
Paulon Säätiö
Sigrid Juselius Foundation
SKR | Varsinais‐Suomen Rahasto
Suomen Kulttuurirahasto
Syöpäsäätiö
Sydäntutkimussäätiö
Turun Yliopisto
Turun Yliopistollinen Keskussairaala
Turun Yliopistosäätiö
- License Information
-
More Information
Article History
Received: 18 December 2022
Revised: 7 March 2023
Accepted: 10 March 2023
First Online: 3 April 2023
Change Date: 21 June 2023
Change Type: Update
Change Details: The copyright line for this article was changed on 21 June 2023 after original online publication.
Disclosure and competing interests statement
: KE has ownership interest in Abomics, Novo Nordisk, Orion, and Roche. JH declares competing financial interests, including direct investments and a role as a medical advisor in Abomics Oy. PT reports personal fees from Roche, AstraZeneca, Bayer and MSD and non‐financial support from MSD, all outside the described work. The other authors declare no conflict of interest.
